Senator asks FDA chief for info relating to Genentech

Share this article:

Sen. Herb Kohl (D-WI) has asked commissioner Andrew von Eschenbach for info relating to the FDA's role in a decision by Genentech to limit availability of its cancer drug Avastin to certain drug compounding pharmacies. Kohl said some physicians have charged that Genentech is taking the step to boost sales of its Lucentis, which is much more expensive than Avastin. 

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.